Clearstone and Mitsubishi Announce Preferred Provider Relationship to Provide Greater Access to Central Lab Services Throughout Asia-Pacific
Clearstone Central Laboratories
announced that it has entered into a partnership with
Mitsubishi Chemical Medience Corporation
(Mitsubishi). This preferred provider relationship provides clients of both companies with access to CAP-accredited laboratories for safety and specialty testing services throughout the Asia-Pacific region and around the world. The cross-collaboration opens access for Mitsubishi clients not only to Clearstone’s lab in China but to its global laboratory network, and creates a new solution for Clearstone clients to access Mitsubishi’s lab network in Japan.
“We are very pleased to announce the Mitsubishi partnership given the value and opportunities it creates for our clients”, said Clearstone CEO Lewis Cameron. “Mitsubishi is well established in Japan, and this agreement extends their reach and capabilities to other strategic markets, including our renowned laboratory in China. We look forward to aligning our operational and business development activities, as well as providing our clients with access to the Japanese market”.
This announcement follows a collaborative agreement that Clearstone signed with the Esoterix Clinical Trials Services division of LabCorp last year.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Regulatory Compliance With eCOAs
April 26th 2024In the fourth and final part of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA discusses how the regulatory stance on electronic clinical outcome assessments has changed over the years and what it could look like in the future.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
Using Patient Reported Outcomes in Dermatology Trials
April 25th 2024In part 3 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA sheds light on the unique challenges of dermatology trials and how clinical outcome assessments can be implemented in them.
